In order to expand its oncology franchise, Amgen has made an offer to acquire Micromet for US$11 per share in cash in a deal that values the company at approximately US$1.16 B. The agreement comes on the back of promising Phase II data for Micromet’s lead asset blinatumomab in acute lymphoblastic leukaemia. With the acquisition, Amgen will also gain the company’s proprietary bispecific T-cell engager (BiTE®) antibody technology and a number of early-stage programmes, the majority of which are partnered.